Flow Cytometry is Now an Integral Component of Comprehensive Immuno-oncology Biomarker Strategy

Written by: JamieThalmann

Published on:
April 25th, 2016

Flow cytometry has long been a mainstay of the diagnostic regime for hematological cancers. Now with the rise of immunotherapies, CGI is at the innovative front establishing a new place for this technology in both hematological and solid tumor cancers. Novel complex protocols, based on individual’s specific genomic profiles, are lacking biomarkers to evaluate the longitudinal multivariate effects of chemotherapy, radiation, resection, checkpoint inhibitors, and vaccines. Traditional reliance on PK/PD data is insufficient to fully inform therapy dose and scheduling. CGI’s newly designed 10 color immune-oncology flow cytometry panel is ideal for evaluating pharmacodynamic biomarker signatures over time. We believe this will become a key tool in addressing the inherent complications of assessing response and dose scheduling in immunotherapy treatments.

We have built this assay on our previous experience in custom panel design for indications such as Multiple Myeloma and Acute Myeloid Leukemia. This has provided us the insight to be able to optimize stock & custom fluorochrome reagent combinations in order to minimize cost and spillover effects. The panel interrogates dynamic changes across comprehensive immune cell populations. Besides the commonly studied subsets, we are able to provide highly accurate immunophenotyping of central memory, effector, effector memory, naïve CD4+ and CD8+ T cells, Tregs, Bregs, NK, and plasmacytoid dendritic cells. Our workflow has been specifically designed to maximize information yield from smaller samples. We have implemented streamlined specimen setup and reporting for turnaround times as short as 24 hours.

At CGI we are constantly innovating around new and existing technologies to further biomarker driven clinical trials and personalized medicine. This is just the latest addition to our burgeoning immune-oncology portfolio and our biopharmaceutical partners are already implementing this flow panel for clinical trials in such indications as glioblastoma.